[Dr.Vad]

Уважаемый профессор Якимов С.В.!

Не могли бы Вы обозначить на основании каких данных октреотид (сандостатин) стал рассматриваться в качестве традиционного эффективного лечения острого панкреатита, когда Ваши коллеги из как минимум 3 стран полагают:

...The results of clinical investigations using somatostatin or its analogue are controversial, since all these trials had low statistical power. In a recent multicenter randomized controlled study with a large number of patients (n = 302) (and an adequate level of disease severity), no benefit of octreotide on progression or outcome was found.

ИЗ Digestion. 1999;60 Suppl 2:23-31.
The role of octreotide and somatostatin in acute and chronic pancreatitis.
Uhl W, Anghelacopoulos SE, Friess H, Buchler MW.
Department of Visceral and Transplantation Surgery, University of Bern, Bern, Switzerland.

...The main focus of the review is the effect of subcutaneous and intravenous administration of octreotide. Analysis of the data suggests that somatostatin could not be recommended for AP and that the efficacy of subcutaneous administration of octreotide is also questionable. Theoretically, intravenous octreotide may be more appropriate for this condition, but recent results with this therapeutic method are limited and contradictory...

Из J Lab Clin Med. 2000 Feb;135(2):112-21.
The effects of somatostatin and octreotide on experimental and human acute pancreatitis.
Greenberg R, Haddad R, Kashtan H, Kaplan O.
Department of Surgery A, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Israel.

...On the basis of these data, we suggest that somatostatin and octreotide should not be recommended for the prevention and treatment of acute pancreatitis.

Из Dig Liver Dis. 2001 Mar;33(2):192-201.
Somatostatin and octreotide in acute pancreatitis: the never-ending story.
Cavallini G, Frulloni L.
Department of Surgical and Gastroenterological Sciences, University of Verona, Italy.